DaVita and Humana Launch Value-Based Care for 10,000+ CKD Patients
DVA sits 75% above its 52-week low of $101.
Summary
DaVita announced a new value-based care agreement with Humana to manage Medicare Advantage members with chronic kidney disease stages 3B-5. The program, launched July 1, will serve more than 10,000 patients and aims to delay or prevent dialysis and reduce hospitalizations. This expands DaVita's existing collaboration with Humana in end-stage kidney disease into earlier disease stages, leveraging its network of 3,000 value-based nephrologist partners. The partnership aligns with DaVita's strategy to grow its integrated kidney care business and could improve patient outcomes while creating a new revenue stream. No financial terms were disclosed, but the scale of the patient population suggests a meaningful expansion of DaVita's value-based care footprint.
At the time of this announcement, DVA was trading at $176.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $11.3B. The 52-week trading range was $101.00 to $247.49. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.